AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 320856 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for 6 months
Number of subjects: 48
Study 7030221 — intervention group
Group type: EXPERIMENTAL
Intervention: Aero-chamber with fenoterol (beta 2 stimulant)
Number of subjects: 10
Study 7030221 — intervention group
Group type: COMPARATOR
Intervention: Standard aerosol inhaler with placebo
Number of subjects: 10
Study 31925473 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multicomponent exercise programme
Number of subjects: 149
Study 31925473 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 149
Study 30203225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 102
Study 30203225 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir plus ribavirin for 12 weeks
Number of subjects: 102
Study 30203225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir
Number of subjects: 102
Study 30203225 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir plus ribavirin
Number of subjects: 102
Study 30203225 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir-velpatasvir and ribavirin
Number of subjects: 102
Study 28578841 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% off-the-shelf Povidone-Iodine (PI)
Number of subjects: 429
Study 28578841 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Povidone-Iodine-based Skin and Nasal Antiseptic (SNA)
Number of subjects: 429
Study 28578841 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 429
Study 26493088 — intervention group
Group type: COMPARATOR
Intervention: Standard lumbar spine imaging reports
Number of subjects: 100
Study 26493088 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports containing prevalence data for common imaging findings in patients without back pain
Number of subjects: 100
Study 23380074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium fluoride
Number of subjects: 75
Study 23380074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 2.4% potassium nitrate and 0.022% sodium fluoride
Number of subjects: 75
Study 23380074 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash containing 0.05% sodium fluoride
Number of subjects: 75
Study 22093205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose eptifibatide (1 μg/kg/min; eCrCl <50 ml/min)
Number of subjects: 8708
Study 22093205 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess dose eptifibatide (2 μg/kg/min; eCrCl <50 ml/min)
Number of subjects: 8708
Study 22093205 — intervention group
Group type: COMPARATOR
Intervention: Early provisional treatment
Number of subjects: 8708
Study 22093205 — intervention group
Group type: COMPARATOR
Intervention: Delayed provisional treatment
Number of subjects: 8708
Study 19520472 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention
Number of subjects: 267
Study 19520472 — intervention group
Group type: COMPARATOR
Intervention: Usual care for orphaned children
Number of subjects: 267
Study 17588225 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg p.o.) with reboxetine (4 mg p.o.)
Number of subjects: 54
Study 17588225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no hydrocortisone or reboxetine)
Number of subjects: 54
Study 15167872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal light stimulation
Number of subjects: 107
Study 15167872 — intervention group
Group type: COMPARATOR
Intervention: No light stimulation
Number of subjects: 107
Study 12401010 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal femoral components
Number of subjects: 101
Study 12401010 — intervention group
Group type: COMPARATOR
Intervention: Anatomic femoral components
Number of subjects: 101
Study 12401010 — intervention group
Group type: COMPARATOR
Intervention: External rotation of the femoral component
Number of subjects: 101
Study 10103294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10103294 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of stimulant medication
Number of subjects: 19
Study 7788958 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg or 500 mg b.i.d.
Number of subjects: 197
Study 7788958 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg or 500 mg t.i.d.
Number of subjects: 197
Study 1979797 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines (specific type not mentioned)
Number of subjects: 0
Study 1979797 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 0
Study 417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20‐120 mg daily)
Number of subjects: 18
Study 417365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31669329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (7 monthly injections)
Number of subjects: 202
Study 31389581 — intervention group
Group type: EXPERIMENTAL
Intervention: B-ultrasound-guided puncture treatment
Number of subjects: 116
Study 31389581 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime and tinidazole (control group)
Number of subjects: 116
Study 28552710 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen deprivation with leuprorelin (Eligard®) for 36 months
Number of subjects: 701
Study 26068865 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN)
Number of subjects: 102
Study 26068865 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin (BBI)
Number of subjects: 102
Study 24368463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy plus amitriptyline
Number of subjects: 135
Study 24368463 — intervention group
Group type: COMPARATOR
Intervention: Headache education plus amitriptyline
Number of subjects: 135
Study 21446795 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermoplastic casts and plastic cups
Number of subjects: 12
Study 21446795 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional technique
Number of subjects: 12
Study 21446795 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 12
Study 19427159 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 105
Study 19427159 — intervention group
Group type: COMPARATOR
Intervention: Magnesium
Number of subjects: 105
Study 19427159 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine+Magnesium
Number of subjects: 105
Study 16415311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5 mg
Number of subjects: 234
Study 16415311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg
Number of subjects: 234
Study 16415311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 234
Study 15776849 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ventricular restoration (SVR)
Number of subjects: 0
Study 15776849 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass alone
Number of subjects: 0
Study 12414003 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 2% plain lignocaine
Number of subjects: 110
Study 12414003 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of 0.9% sodium chloride solution (placebo)
Number of subjects: 110
Study 9797057 — intervention group
Group type: EXPERIMENTAL
Intervention: Root form bioactive glass cones in bone splitting (BS) group
Number of subjects: 16
Study 9797057 — intervention group
Group type: EXPERIMENTAL
Intervention: Root form bioactive glass cones in fresh extraction sockets (FES) group
Number of subjects: 16
Study 9797057 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with conventional extraction sockets
Number of subjects: 16
Study 7611396 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 20
Study 2236458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dosage 165 +/- 19 mg/day, reduced from 270 +/- 20 mg/day)
Number of subjects: 10
Study 2236458 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (initial dosage 270 +/- 20 mg/day)
Number of subjects: 10
Study 78260 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mastectomy combined with radical radiotherapy
Number of subjects: 0
Study 78260 — intervention group
Group type: COMPARATOR
Intervention: Simple mastectomy alone
Number of subjects: 0
Study 29476416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing case-management intervention over 12 months
Number of subjects: 0
Study 29476416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27430425 — intervention group
Group type: EXPERIMENTAL
Intervention: sarolaner (Simparica™ Chewables) administered monthly for 3 months (2 to 4 mg/kg)
Number of subjects: 24
Study 27430425 — intervention group
Group type: COMPARATOR
Intervention: fluralaner (Bravecto®) administered as a single dose (25 to 56 mg/kg)
Number of subjects: 24
Study 23085086 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha binaural beat of 10 Hz
Number of subjects: 22
Study 23085086 — intervention group
Group type: COMPARATOR
Intervention: Beta binaural beat of 20 Hz
Number of subjects: 22
Study 22033712 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC
Number of subjects: 517
Study 22033712 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix coils
Number of subjects: 517
Study 20426626 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte telomere repeat copy number to single gene copy number (TSR)
Number of subjects: 518
Study 17608868 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alert system for pharmacists (intervention group)
Number of subjects: 59840
Study 17608868 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 59840
Study 15649674 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to increase collaboration between general practitioners and occupational health physicians
Number of subjects: 112
Study 15649674 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 112
Study 11863106 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial fecal occult blood screening (FOBT)
Number of subjects: 0
Study 11863106 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual fecal occult blood screening (FOBT)
Number of subjects: 0
Study 11863106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening mentioned)
Number of subjects: 0
Study 10502861 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer monitor tachistoscopes (CRT)
Number of subjects: 0
Study 10502861 — intervention group
Group type: COMPARATOR
Intervention: Conventional tachistoscopes
Number of subjects: 0
Study 7548266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 150 mg daily
Number of subjects: 34
Study 7548266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg tid for 28 days
Number of subjects: 34
Study 7548266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7548266 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil
Number of subjects: 34
Study 1949361 — intervention group
Group type: EXPERIMENTAL
Intervention: Robinson gravity system
Number of subjects: 140
Study 1949361 — intervention group
Group type: COMPARATOR
Intervention: Redon drainage system
Number of subjects: 140
Study 7036825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g daily intake of oral erythromycin base
Number of subjects: 48
Study 7036825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31436295 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-TOF-MS method for GP screening
Number of subjects: 1091
Study 31436295 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-TOF-MS method for PGL screening
Number of subjects: 1091
Study 31436295 — intervention group
Group type: EXPERIMENTAL
Intervention: LC-MS-MS confirmation testing for GP and PGL
Number of subjects: 1091
Study 31436295 — intervention group
Group type: COMPARATOR
Intervention: LC-MS-MS testing of previously negative specimens
Number of subjects: 1091
Study 29059277 — intervention group
Group type: EXPERIMENTAL
Intervention: Active referral group
Number of subjects: 1226
Study 29059277 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice group
Number of subjects: 1226
Study 29059277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1226
Study 24571261 — intervention group
Group type: EXPERIMENTAL
Intervention: ERT combined with PVP
Number of subjects: 137
Study 24571261 — intervention group
Group type: COMPARATOR
Intervention: ERT
Number of subjects: 137
Study 24571261 — intervention group
Group type: COMPARATOR
Intervention: PVP
Number of subjects: 137
Study 24571261 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 137
Study 24933720 — intervention group
Group type: EXPERIMENTAL
Intervention: High reward (HR)
Number of subjects: 10
Study 22448255 — intervention group
Group type: EXPERIMENTAL
Intervention: Well Woman Exam (WWE)
Number of subjects: 0
Study 22448255 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Educational Sessions (4ES)
Number of subjects: 0
Study 22448255 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention (SI)
Number of subjects: 0
Study 21085661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetris
Number of subjects: 0
Study 21085661 — intervention group
Group type: COMPARATOR
Intervention: Pub Quiz
Number of subjects: 0
Study 21085661 — intervention group
Group type: COMPARATOR
Intervention: No-task control
Number of subjects: 0
Study 17617940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 g/d plant sterol supplementation
Number of subjects: 309
Study 17617940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g/d plant sterol supplementation
Number of subjects: 309
Study 17617940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 16364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=35)
Number of subjects: 75
Study 16364999 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 75
Study 12162476 — intervention group
Group type: EXPERIMENTAL
Intervention: gatifloxacin (400 mg po 1 h)
Number of subjects: 12
Study 12162476 — intervention group
Group type: EXPERIMENTAL
Intervention: oxycodone (5 mg po Q4H)
Number of subjects: 12
Study 12162476 — intervention group
Group type: COMPARATOR
Intervention: gatifloxacin/oxycodone regimen
Number of subjects: 12
Study 10658860 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (n = 14)
Number of subjects: 30
Study 10658860 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (n = 16)
Number of subjects: 30
Study 7604800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily
Number of subjects: 40
Study 7604800 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate 400 mg once daily
Number of subjects: 40
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit preparation instruction
Number of subjects: 0
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit preparation instruction
Number of subjects: 0
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Random presentation mode of preparation intervals
Number of subjects: 0
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked presentation mode of preparation intervals
Number of subjects: 0
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of implicit/explicit instructions and random/blocked presentation modes
Number of subjects: 0
Study 1481703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedural variables (implicit/explicit instructions and presentation modes)
Number of subjects: 0
Study 3969867 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg every 2 hours for 72 hours
Number of subjects: 41
Study 3969867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 30048216 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up (TFU)
Number of subjects: 82
Study 30048216 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 82
Study 28383294 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II (B‐II)
Number of subjects: 162
Study 28383294 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y (R‐Y)
Number of subjects: 162
Study 26878788 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine polyphenol intake (WPI; 733 equivalents of gallic acid/day) for 28 days
Number of subjects: 57
Study 26250580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone
Number of subjects: 0
Study 23312690 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176
Study 23312690 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 176
Study 20875945 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Group's Autobiographical Memory Test (initial evaluation)
Number of subjects: 63
Study 20875945 — intervention group
Group type: COMPARATOR
Intervention: Working Group's Autobiographical Memory Test (follow-up evaluation)
Number of subjects: 63
Study 20875945 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Group's Autobiographical Memory Test (test items)
Number of subjects: 63
Study 18363889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg for 4 days)
Number of subjects: 24
Study 16797384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention targeting specific barriers (e.g., poor nutritional knowledge, help needed with shopping or cooking, difficulty swallowing)
Number of subjects: 180
Study 16797384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention targeting specific barriers
Number of subjects: 180
Study 16797384 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 180
Study 12941041 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (n = 122)
Number of subjects: 248
Study 12941041 — intervention group
Group type: COMPARATOR
Intervention: No substitution (Control group, n = 126)
Number of subjects: 248
Study 12212131 — intervention group
Group type: EXPERIMENTAL
Intervention: New mode CS (peritoneum not sewed)
Number of subjects: 468
Study 12212131 — intervention group
Group type: EXPERIMENTAL
Intervention: New mode CS (peritoneum sewed)
Number of subjects: 468
Study 12212131 — intervention group
Group type: COMPARATOR
Intervention: Lower segmental CS
Number of subjects: 468
Study 9200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated BMT
Number of subjects: 96
Study 9200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic-related BMT
Number of subjects: 96
Study 9200994 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 96
Study 8427238 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein‐sparing modified fast diet (2520 to 3360 J)
Number of subjects: 19
Study 8427238 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric balanced diet (3360 to 4200 J)
Number of subjects: 19
Study 8427238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets combined
Number of subjects: 19
Study 3118061 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile gauze, replaced every other day
Number of subjects: 2088
Study 3118061 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze
Number of subjects: 2088
Study 3118061 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent polyurethane dressing
Number of subjects: 2088
Study 3118061 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor-transparent dressing
Number of subjects: 2088
Study 26460106 — intervention group
Group type: EXPERIMENTAL
Intervention: Felt stigma scale (8-item scale)
Number of subjects: 1184
Study 26460106 — intervention group
Group type: EXPERIMENTAL
Intervention: Enacted stigma scale (4-item scale)
Number of subjects: 1184
Study 26460106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stigma scales
Number of subjects: 1184
Study 26011241 — intervention group
Group type: EXPERIMENTAL
Intervention: ORC/collagen matrix plus foam dressing (TIELLE®)
Number of subjects: 33
Study 26011241 — intervention group
Group type: COMPARATOR
Intervention: Foam dressing (TIELLE®)
Number of subjects: 33
Study 24645966 — intervention group
Group type: COMPARATOR
Intervention: Single-dose (PEG 4 L the day before the study)
Number of subjects: 180
Study 24645966 — intervention group
Group type: COMPARATOR
Intervention: Split-dose (2 L the day before and 2 L on the day of the procedure)
Number of subjects: 180
Study 24645966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume (2 L PEG solution the day of the procedure)
Number of subjects: 180
Study 22453319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 60
Study 22453319 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of lignans (mean intake 1224 mug/d, sd 539)
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of lignans
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of rye products, berries, coffee, tea and roots
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of rye products and coffee
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of water-insoluble fibre
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of vegetables and rye products
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of water-soluble fibre
Number of subjects: 100
Study 19811696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of lariciresinol
Number of subjects: 100
Study 17617528 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan plus cisplatin
Number of subjects: 0
Study 17617528 — intervention group
Group type: EXPERIMENTAL
Intervention: Various doublets, triplets, and quartlets
Number of subjects: 0
Study 17617528 — intervention group
Group type: COMPARATOR
Intervention: Single-agent cisplatin
Number of subjects: 0